Following George Joulwan’s last EBS Sell transaction on June 12, 2018, the stock climbed by 15.8%. In addition to George Joulwan, one other EBS executive reported Sell trades in the last month.
Based on Emergent Biosolutions’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $174 million and quarterly net profit of $20.95 million. In comparison, last year the company earned revenue of $149 million and had a net profit of $33.55 million. EBS’s market cap is $3.49B and the company has a P/E ratio of 35.55. Currently, Emergent Biosolutions has an average volume of 423.2K.
Based on 5 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $69.80, reflecting a 3.3% upside.
The insider sentiment on Emergent Biosolutions has been positive according to 54 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures that address public health and national security threats. It includes Chemical, Biological, Radiological, Nuclear and Explosive or CBRNE threats; as well as emerging infectious diseases.